Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
meeting tags : Clinical-trials-phase-iii save search
KalVista Pharmaceuticals to Present Phase 3 Sebetralstat Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting
Published: 2024-02-16 (Crawled : 12:30) - biospace.com/
KALV | News | $10.34 -7.76% -8.41% 420K
|
Health Technology
|
| O: -0.68%
H: 2.32%
C: 1.36%
sebetralstat pharmaceuticals immunology meeting
Geron Announces Data Presentations from IMerge Phase 3 Evaluating Imetelstat in Lower Risk MDS at Society of Hematologic Oncology Annual Meeting
Published: 2023-09-07 (Crawled : 17:00) - biospace.com/
GERN | $3.57 2.0% 1.96% 6.6M
|
Health Technology
|
| O: 0.0%
H: 2.04%
C: 0.0%
risk meeting
Phase 3 MARIPOSA-2 Study Meets Dual Primary Endpoint Resulting in Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival for RYBREVANT®
Published: 2023-09-06 (Crawled : 17:00) - biospace.com/
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: -0.37%
H: 0.0%
C: 0.0%
rybrevant study
Seagen Phase 3 Trial of TUKYSA® (tucatinib) in Combination with Antibody-Drug Conjugate ado-trastuzumab emtansine Meets Primary Endpoint of Progression-Free Survival in Patients with Previously Treated HER2-Positive Metastatic Breast Cancer
Published: 2023-08-16 (Crawled : 13:00) - biospace.com/
SGEN | $228.74 0.1% 20M
|
Health Technology
|
| O: -0.02%
H: 0.39%
C: -0.42%
tukysa breast cancer trial
Takeda Presents Full Data Set from Phase 3 ADVANCE-CIDP 1 Clinical Trial Investigating HYQVIA® as a Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) at PNS Annual Meeting
Published: 2023-06-20 (Crawled : 14:00) - biospace.com/
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: 0.25%
H: 0.31%
C: -0.12%
hyqvia meeting set trial therapy
ImmunoGen Announces Results from the Phase 3 MIRASOL Trial Selected as Late-Breaking Presentation for ASCO 2023 Annual Meeting
Published: 2023-05-09 (Crawled : 12:00) - biospace.com/
IMGN | News | $31.23 0.03% 49M
|
Health Technology
|
| O: -0.15%
H: 4.8%
C: 3.23%
presentation asco meeting trial results
RenovoRx Presenting Phase III Clinical Trial Interim Analysis Data of the TIGeR-PaC Study at American Association for Cancer Research Annual Meeting Underway in Orlando, Florida
Published: 2023-04-14 (Crawled : 13:00) - biospace.com/
RNXT | $1.26 5.0% 4.76% 3.5K
|
|
| O: -0.37%
H: 5.64%
C: 5.26%
association cancer research meeting trial study
Soligenix Announces Scheduling of Type A Meeting with the U.S. FDA for HyBryte™ New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma
Published: 2023-04-03 (Crawled : 19:00) - biospace.com/
SNGX | $0.385 -3.75% -3.9% 490K
|
Health Technology
|
| O: -3.55%
H: 11.45%
C: 6.32%
fda drug t-cell treatment meeting application
Phase 3 DISSOLVE Program of SEL-212 in Chronic Refractory Gout Meets Primary Endpoint: Swedish Orphan Biovitrum AB
Published: 2023-03-21 (Crawled : 11:00) - biospace.com/
SELB 4 | $0.8812 -8.0% 2.12% 0
|
Health Technology
|
| O: 7.03%
H: 0.73%
C: -8.03%
sel-212 program
Abeona Therapeutics Announces Acceptance of Abstract on EB-101 Phase 3 VIITAL™ Study Results for Oral Presentation at International Societies for Investigative Dermatology (ISID) 2023 Meeting
Published: 2023-03-16 (Crawled : 12:20) - biospace.com/
ABEO | News | $3.165 -7.19% -7.74% 2.2M
|
Health Technology
|
| O: -2.29%
H: 3.52%
C: -0.78%
eb-101 presentation international meeting therapeutics study
POINT Biopharma Completes Randomization in PNT2002’s Phase 3 SPLASH TrialEnrollment for the randomization phase of SPLASH completed prior to EOY 2022, meeting previous guidance
Published: 2023-01-12 (Crawled : 15:00) - biospace.com/
PNT | $13.68 2.63% 0.15% 0
|
|
| O: -0.14%
H: 7.24%
C: 6.21%
LNTH | $65.19 1.21% 1.2% 580K
|
Health Technology
|
| O: 0.42%
H: 3.8%
C: 2.11%
pnt2002 biopharma meeting
Immutep Announces Successful Meeting with the FDA on Eftilagimod Alpha plus Chemotherapy for the Treatment of Metastatic Breast Cancer
Published: 2022-12-23 (Crawled : 16:00) - biospace.com/
IMMP | $2.59 3.19% 3.09% 1.4M
|
Health Technology
|
| O: 10.58%
H: 0.48%
C: -4.31%
treatment fda meeting breast plus cancer metastatic breast cancer
Aldeyra Therapeutics Announces Oral Presentation of Phase 3 Data at the American Academy of Optometry 2022 Annual Meeting
Published: 2022-10-26 (Crawled : 13:20) - biospace.com/
ALDX | $3.93 0.51% 0.51% 570K
|
Health Technology
|
| O: 0.0%
H: 8.0%
C: 7.81%
meeting therapeutics presentation
New Data Presented at the American College of Gastroenterology Annual Scientific Meeting Demonstrate Continuous Zeposia (ozanimod) Treatment Prevents Disease Relapse Over One Year
Published: 2022-10-24 (Crawled : 12:00) - biospace.com/
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: 0.62%
H: 1.24%
C: 0.45%
treatment disease meeting year one
Scholar Rock to Present Data from the Phase 1 DRAGON trial at the SITC 37th Annual Meeting
Published: 2022-10-06 (Crawled : 19:00) - biospace.com/
SRRK 4 | $14.11 -4.6% -4.82% 430K
|
Health Technology
|
| O: 0.75%
H: 7.68%
C: 0.12%
meeting trial phase 1
XORTX Completes Positive Pre-Phase 3 Meeting with the US Food and Drug Administration
Published: 2022-09-19 (Crawled : 12:00) - biospace.com/
XRTX | News | $2.88 -2.41% 11K
|
Mining, Quarrying, and Oil and ...
|
| O: 1.69%
H: 2.95%
C: -8.57%
drug meeting food positive
Alnylam to Present Additional Data from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy at the Heart Failure Society of America Annual Scientific Meeting 2022
Published: 2022-09-13 (Crawled : 13:00) - biospace.com/
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: 1.78%
H: 0.0%
C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.97%
H: 0.16%
C: -0.98%
ALNY | $143.8 -1.55% -1.58% 390K
|
Health Technology
|
| O: -1.77%
H: 0.54%
C: -0.8%
america meeting heart study
Bellus Health Announces Positive End-of-Phase 2 Meeting with the FDA and its CALM Phase 3 Program for BLU-5937 in Refractory Chronic Cough
Published: 2022-07-12 (Crawled : 12:00) - biospace.com/
BLU | $14.74 0.03% 0
|
Health Technology
|
| O: -9.67%
H: 2.37%
C: -0.41%
blu-5937 fda meeting health program positive phase 3 phase 2
Treatment With Hepcludex® (Bulevirtide) Meets Primary Endpoint and Achieves Significant Response in Chronic Hepatitis Delta Virus at 48 Weeks
Published: 2022-06-23 (Crawled : 16:00) - biospace.com/
GILD | $67.07 0.06% 0.06% 8.3M
|
Health Technology
|
| O: 0.5%
H: 0.0%
C: 0.0%
hepcludex treatment hepatitis virus response
Momelotinib Pivotal Phase 3 Data Receives Oral Presentation at American Society of Clinical Oncology Annual Meeting
Published: 2022-05-26 (Crawled : 00:00) - biospace.com/
SRRA | $54.99 0.04% 0.0%
|
Health Technology
|
| O: 0.05%
H: 0.0%
C: 0.0%
presentation phase 3
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.